Unknown

Dataset Information

0

Treatment for COVID-19: An overview.


ABSTRACT: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a characteristic hyperinflammatory response, vascular damage, microangiopathy, angiogenesis and widespread thrombosis. Four stages of COVID-19 have been identified: the first stage is characterised by upper respiratory tract infection; the second by the onset of dyspnoea and pneumonia; the third by a worsening clinical scenario dominated by a cytokine storm and the consequent hyperinflammatory state; and the fourth by death or recovery. Currently, no treatment can act specifically against the SARS-CoV-2 infection. Based on the pathological features and different clinical phases of COVID-19, particularly in patients with moderate to severe COVID-19, the classes of drugs used are antiviral agents, inflammation inhibitors/antirheumatic drugs, low molecular weight heparins, plasma, and hyperimmune immunoglobulins. During this emergency period of the COVID-19 outbreak, clinical researchers are using and testing a variety of possible treatments. Based on these premises, this review aims to discuss the most updated pharmacological treatments to effectively act against the SARS-CoV-2 infection and support researchers and clinicians in relation to any current and future developments in curing COVID-19 patients.

SUBMITTER: Stasi C 

PROVIDER: S-EPMC7548059 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment for COVID-19: An overview.

Stasi Cristina C   Fallani Silvia S   Voller Fabio F   Silvestri Caterina C  

European journal of pharmacology 20201011


Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a characteristic hyperinflammatory response, vascular damage, microangiopathy, angiogenesis and widespread thrombosis. Four stages of COVID-19 have been identified: the first stage is characterised by upper respiratory tract infection; the second by the onset of dyspnoea and pneumonia; the third by a worsening clinical scenario dominated by a cytokine  ...[more]

Similar Datasets

| S-EPMC9774286 | biostudies-literature
| S-EPMC7179549 | biostudies-literature
| S-EPMC7205601 | biostudies-literature
| S-EPMC7167217 | biostudies-literature
| S-BSST563 | biostudies-other
| S-EPMC8106485 | biostudies-literature
| S-EPMC9192965 | biostudies-literature
| S-EPMC7260446 | biostudies-literature
| S-EPMC7753885 | biostudies-literature
| S-EPMC7266424 | biostudies-literature